Stay updated on Nivolumab vs Investigator's Choice in Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs Investigator's Choice in Head and Neck Cancer Clinical Trial page.

Latest updates to the Nivolumab vs Investigator's Choice in Head and Neck Cancer Clinical Trial page
- Check10 days agoChange DetectedThe page adds Head and neck squamous cell carcinoma and related topics (MedlinePlus Genetics) and expands the list of locations, while removing several location blocks.SummaryDifference2%

- Check18 days agoChange DetectedRemoved the disease focus 'Head and neck squamous cell carcinoma' and the related topic 'MedlinePlus Genetics' from the page.SummaryDifference0.1%

- Check25 days agoChange DetectedAdded topic 'Head and neck squamous cell carcinoma' and related MedlinePlus Genetics links on the page.SummaryDifference0.1%

- Check39 days agoChange DetectedPublications section wording updated to state that publications are automatically filled from PubMed and may not be about the study, and the revision tag changed from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check47 days agoChange DetectedDeleted the government funding status notice from the page; no core trial information (eligibility criteria, interventions, outcomes) was changed.SummaryDifference0.2%

- Check54 days agoChange DetectedAdded location: Tainan, Taiwan, 704, and removed location: Tainan City, Taiwan, 704 from the study locations.SummaryDifference0.0%

Stay in the know with updates to Nivolumab vs Investigator's Choice in Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Investigator's Choice in Head and Neck Cancer Clinical Trial page.